Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Field Medical Execution Despite Limited Resources
Summary
In this episode, Ed Cunningham delves into his extensive background in Neurology MSLs and shares insights on managing MSL teams, including the role of outsourcing. He explores the impact of virtual platforms and technology on MSL interactions, and offers strategies for engaging KOLs in the post-COVID landscape. Ed addresses the challenges of maintaining effectiveness in large territories, and discusses metrics for performance measurement in Medical Affairs. The conversation extends to the future of the MSL role, hybrid work models, and the evolving value of MSLs to stakeholders. The episode concludes with closing remarks and sponsorship from Synovian Pharmaceuticals.
My guest today is Ed Cunningham, Executive Director, Neurology MSLs with Sunovian Pharmaceuticals shares insights for Field Medical Execution Despite Limited Resources
Ed discusses…
👉 How to lead MSL teams with limited resources
👉 The importance of outsourcing to support field-based efforts and activities
👉 Virtual and alternative platforms to share data and gather insights
👉 What are best practices for prioritizing KOL engagement and tracking
👉 How budget plays a factor
👉 How an MSL can maintain effectiveness in a very large territory
👉 How an MSL can adapt a territory plan to accomplish objectives
Neurology MSLs, managing MSL teams, virtual platforms impact, engaging KOLs strategies, future of MSL role
Related Topics
You May Also Like
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis